|MONDAY, JULY 12
Session 2: Developing Rational Strategies for Combination Therapy
Chairperson: Jeffrey Settleman, Genentech, Inc., South San Francisco, CA
8:00 a.m.-10:00 a.m.
Modeling drug sensitivity and resistance in human tumor-derived cell lines
Predictors of RAS/RAF dependence
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY
Rational integration of HDAC inhibitors into cancer therapy
Pamela N. Munster, University of California, San Francisco, CA
Targeting redundancy in RAS-PI3K signaling in NSCLC
Hayley M. McDaid, Albert Einstein College of Medicine, Bronx, NY
Session 3: Implementing Genomics/Genetics in Day-to-Day Clinical Practice
Chairperson: Joseph R. Nevins, Duke University Medical Center, Durham, NC
10:30 a.m.-12:30 p.m.
Variables for individualizing systemic therapy in patients with lung cancer
Gerold Bepler, Karmanos Cancer Institute, Detroit, MI
Utilization of genomic signatures to guide therapeutic decisions
Joseph R. Nevins
Personalized cancer diagnostics
Christopher L. Corless, Oregon Health & Science University, Portland, OR
Genetic testing for breast and ovarian cancer: From risk assessment to therapeutic targeting
Susan M. Domchek, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA
Mentoring Lunches for Early-Career Investigators
12:30 p.m.-2:00 p.m.
Session 4: Novel Trial Design and Companion Diagnostics
Chairperson: Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX
2:00 p.m.-4:00 p.m.
Gene-based trial matching
Timothy J. Yeatman, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Toward personalized therapy for advanced non-small cell lung cancer: The M. D. Anderson BATTLE Programs
Roy S. Herbst
The biomarker roadmap: How to integrate biomarker and compound discovery for early clinical decision making
Pearl S. Huang, Merck & Co., Inc., North Wales, PA
Design of phase III clinical trials for predictive oncology
Richard M. Simon, NCI-DCTD, Bethesda, MD
Oral Presentations from Proffered Abstracts
4:00 p.m.-5:00 p.m.
Genomic discovery of CD44-SLC1A2 gene fusions in gastric cancer
Jiong Tao, National University of Singapore, Singapore
Therapeutic intervention targeting a Hedgehog-dependent barrier to drug delivery in pancreatic cancer
Kenneth P. Olive, Columbia University, New York, NY
Preclinical and molecular profiling data suggest LumB breast cancer as a potential indication for co-targeting IGF1R and mTOR with MK-0646 and MK-8669
Theresa Zhang, Merck & Co., Inc., Boston, MA
Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia
Nicolas Stransky, The Broad Institute, Cambridge, MA
Poster Session A
5:00 p.m.-7:00 p.m.